OpenAI-funded Biossil snags Theriva's unwanted antibiotic degrader portfolio for up to $91M
Fierce Biotech ·
In brief: Fierce Biotech reported on 2 Nov 2026: “OpenAI-funded Biossil snags Theriva's unwanted antibiotic degrader portfolio for up to $91M”. This page links to the original article and to related global AI stories tracked by Deekoya AI.
Read the full story on Fierce BiotechExplore more: Today in AI · Research papers · AI tools · Learn AI
Related stories
- Healthcare Dive · 3 Nov 2026AI vendors, health systems join physicians in liability for clinical AI
- Business Insider · 3 Nov 2026Claude's new AI report card tool gives companies a closer look at costs — and flags 'inefficiencies'
- CU Today · 3 Nov 2026Wells Fargo Tells Customers: If Your AI Agent Goes Rogue, You May Be Liable
- Kalkine Media · 3 Nov 2026How could rising AI regulation shape WhiteHawk's (ASX:WHK) next phase?
- Tech Xplore · 3 Nov 2026Humanoid AI connects walking and object handling without demonstrations of complete task sequences
- Consumer Finance Monitor · 3 Nov 2026Pennsylvania Enacts Artificial Intelligence Deceptive Advertising Act: New Disclosure Requirements for AI-Generated Advertising
Who reported “OpenAI-funded Biossil snags Theriva's unwanted antibiotic degrader portfolio…”?
Fierce Biotech, on 2 Nov 2026. The full article is at the source link on this page.